Detecting Alzheimer's Disease Using Blood Tests and Machine Learning
Screening for Alzheimer's Disease Based on Raman Spectroscopy of Blood
This study is working on a new way to help spot Alzheimer's disease early by looking at blood samples with a special technique, and it needs patients to provide their blood so we can find out if this method can help catch the disease up to 20 years before symptoms show.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Early Alzheimer's Diagnostics LLC NIH-funded |
| Lab location | 1 site (Glenmont, United States) |
| Project ID | NIH-10547295 on NIH RePORTER |
What this research studies
This research aims to develop a new diagnostic tool for Alzheimer's disease (AD) by utilizing Raman spectroscopy to analyze blood samples. By applying machine learning algorithms, the study seeks to identify specific changes in blood biomarkers that may indicate the early stages of AD, potentially up to 20 years before symptoms appear. This innovative approach could provide a non-invasive and accessible method for early detection, allowing for timely interventions to preserve cognitive health. Patients will be involved in providing blood samples for analysis, contributing to the advancement of this promising diagnostic technology.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk for Alzheimer's disease, particularly those with a family history or early cognitive changes.
Not a fit: Patients with advanced Alzheimer's disease or those who do not have any risk factors for the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of Alzheimer's disease, enabling timely treatment and better management of the condition.
How similar studies have performed: Other research has shown promise in using machine learning and biomarker analysis for early detection of Alzheimer's, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Glenmont, United States
- Early Alzheimer's Diagnostics LLC — Glenmont, United States (Active)
Researchers
- Principal investigator: Lednev, Igor K — Early Alzheimer's Diagnostics LLC
- Study coordinator: Lednev, Igor K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.